These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37854499)

  • 1. Evaluation of the liver targeting and anti‑liver cancer activity of artesunate‑loaded and glycyrrhetinic acid‑coated nanoparticles.
    Pan XW; Huang JS; Liu SR; Shao YD; Xi JJ; He RY; Shi TT; Zhuang RX; Bao JF
    Exp Ther Med; 2023 Nov; 26(5):516. PubMed ID: 37854499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation, evaluation, and
    Pan X; Liu S; Ju L; Xi J; He R; Zhao Y; Zhuang R; Huang J
    Drug Dev Ind Pharm; 2020 Nov; 46(11):1889-1897. PubMed ID: 32975456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
    Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
    Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional nanoplatform based on star-shaped copolymer for liver cancer targeting therapy.
    Gong X; Zheng Y; He G; Chen K; Zeng X; Chen Z
    Drug Deliv; 2019 Dec; 26(1):595-603. PubMed ID: 31195837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific cellular internalization and pH-responsive behavior of doxorubicin loaded PLGA-PEG nanoparticles targeted with anti EGFRvIII antibody.
    Eivazi N; Rahmani R; Paknejad M
    Life Sci; 2020 Nov; 261():118361. PubMed ID: 32861796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
    Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W
    Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
    Lin TsT; Gao DY; Liu YC; Sung YC; Wan D; Liu JY; Chiang T; Wang L; Chen Y
    J Control Release; 2016 Jan; 221():62-70. PubMed ID: 26551344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, characterization, and evaluation of in vitro cytotoxicity and in vivo antitumor activity of asiatic acid-loaded poly lactic-co-glycolic acid nanoparticles: A strategy of treating breast cancer.
    Dutta S; Chakraborty P; Basak S; Ghosh S; Ghosh N; Chatterjee S; Dewanjee S; Sil PC
    Life Sci; 2022 Oct; 307():120876. PubMed ID: 35961595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polysaccharide-modified nanoparticles with intelligent CD44 receptor targeting ability for gene delivery.
    Lin WJ; Lee WC
    Int J Nanomedicine; 2018; 13():3989-4002. PubMed ID: 30022822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into glycyrrhetinic acid: the role of the hydroxyl group on liver targeting.
    Tian Q; Wang X; Wang W; Zhang C; Liu Y; Yuan Z
    Int J Pharm; 2010 Nov; 400(1-2):153-7. PubMed ID: 20813176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
    Vangara KK; Liu JL; Palakurthi S
    Anticancer Res; 2013 Jun; 33(6):2425-34. PubMed ID: 23749891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate receptor-targeted PLGA-PEG nanoparticles for enhancing the activity of genistein in ovarian cancer.
    Patra A; Satpathy S; Naik PK; Kazi M; Hussain MD
    Artif Cells Nanomed Biotechnol; 2022 Dec; 50(1):228-239. PubMed ID: 36330543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor.
    Alam N; Koul M; Mintoo MJ; Khare V; Gupta R; Rawat N; Sharma PR; Singh SK; Mondhe DM; Gupta PN
    Biomed Pharmacother; 2017 Nov; 95():856-864. PubMed ID: 28903181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plumbagin-loaded aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol nanoparticles for prostate cancer therapy.
    Pan M; Li W; Yang J; Li Z; Zhao J; Xiao Y; Xing Y; Zhang X; Ju W
    Medicine (Baltimore); 2017 Jul; 96(30):e7405. PubMed ID: 28746182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
    Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
    Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate-receptor-targeted laser-activable poly(lactide-
    Liu F; Chen Y; Li Y; Guo Y; Cao Y; Li P; Wang Z; Gong Y; Ran H
    Int J Nanomedicine; 2018; 13():5139-5158. PubMed ID: 30233177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferential tumor accumulation and desirable interstitial penetration of poly(lactic-co-glycolic acid) nanoparticles with dual coating of chitosan oligosaccharide and polyethylene glycol-poly(D,L-lactic acid).
    Wang G; Chen Y; Wang P; Wang Y; Hong H; Li Y; Qian J; Yuan Y; Yu B; Liu C
    Acta Biomater; 2016 Jan; 29():248-260. PubMed ID: 26476340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of long-circulating nanoparticles loaded with betulinic acid for improved anti-tumor efficacy.
    Saneja A; Kumar R; Singh A; Dhar Dubey R; Mintoo MJ; Singh G; Mondhe DM; Panda AK; Gupta PN
    Int J Pharm; 2017 Oct; 531(1):153-166. PubMed ID: 28823888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered nanomedicine for myeloma and bone microenvironment targeting.
    Swami A; Reagan MR; Basto P; Mishima Y; Kamaly N; Glavey S; Zhang S; Moschetta M; Seevaratnam D; Zhang Y; Liu J; Memarzadeh M; Wu J; Manier S; Shi J; Bertrand N; Lu ZN; Nagano K; Baron R; Sacco A; Roccaro AM; Farokhzad OC; Ghobrial IM
    Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10287-92. PubMed ID: 24982170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.